Aramchol arachidyl amino cholanoic acid: Phase IIa started

Galmed began the double-blind, placebo-controlled, U.S. Phase IIa ARRIVE trial to evaluate 600 mg oral Aramchol once daily for 12 weeks in up to 50 patients with HIV-associated lipodystrophy and NAFLD...